AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26849141 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinity Evolution (TE) with PEEK interbody spacer
Number of subjects: 31
Study 24521153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle coaching approaches (problem-solving, self-monitoring skills)
Number of subjects: 1076
Study 24521153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle coaching approaches (problem-solving)
Number of subjects: 1076
Study 24521153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle coaching approaches (more costly approaches)
Number of subjects: 1076
Study 24349492 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RBD
Number of subjects: 18
Study 24349492 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study 24349492 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RBD (daytime consolidation)
Number of subjects: 18
Study 24349492 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RBD (sleep talking)
Number of subjects: 18
Study 24349492 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RBD (dementia)
Number of subjects: 18
Study 20962352 — intervention group
Group type: EXPERIMENTAL
Intervention: Canaloplasty (360° catheterisation of Schlemm's canal with a flexible microcatheter and tensioning 10‐0 polypropylene suture)
Number of subjects: 60
Study 20962352 — intervention group
Group type: EXPERIMENTAL
Intervention: Canaloplasty
Number of subjects: 60
Study 18412805 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of botulinum toxin type A applied to the dominant (right) hand
Number of subjects: 8
Study 18412805 — intervention group
Group type: COMPARATOR
Intervention: Normal saline applied to the non-dominant (left) hand (Control)
Number of subjects: 8
Study 16796458 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous postoperative teleradiotherapy and radioimmunotherapy (TRT + RIT)
Number of subjects: 18
Study 16796458 — intervention group
Group type: COMPARATOR
Intervention: Teleradiotherapy alone (TRT)
Number of subjects: 18
Study 12641503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU) and calcium citrate (800 mg) daily (group A)
Number of subjects: 84
Study 12641503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (25 mg b.d., group B)
Number of subjects: 84
Study 12641503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (1 mg every 3 months, group C)
Number of subjects: 84
Study 10890672 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli)
Number of subjects: 12
Study 10890672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (cyclooxygenase inhibitor)
Number of subjects: 12
Study 10890672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8615317 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal monophasic shock
Number of subjects: 20
Study 8615317 — intervention group
Group type: COMPARATOR
Intervention: Cathodal biphasic shock
Number of subjects: 20
Study 1479464 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquavene test catheter
Number of subjects: 63
Study 1479464 — intervention group
Group type: COMPARATOR
Intervention: Teflon control catheter
Number of subjects: 63
Study 6589106 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered rotary toothbrush
Number of subjects: 10
Study 6589106 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand brush
Number of subjects: 10
Study 30780196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine combined with cognitive behaviour intervention therapy
Number of subjects: 82
Study 28278599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 488
Study 28278599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488
Study 28278599 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and sertraline
Number of subjects: 488
Study 28278599 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study 27419388 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise program (3 times weekly for 4 months on a bicycle ergometer at 60-70% heart rate reserve)
Number of subjects: 44
Study 27419388 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study 25591513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceraxon (citicoline)
Number of subjects: 120
Study 25591513 — intervention group
Group type: EXPERIMENTAL
Intervention: Management rules
Number of subjects: 120
Study 22682213 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment received during the trial
Number of subjects: 100
Study 22682213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention adherence
Number of subjects: 100
Study 22682213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability of assessments
Number of subjects: 100
Study 22682213 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding of assessments
Number of subjects: 100
Study 19733016 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative continuous accelerated irradiation (p‐CAIR) therapy
Number of subjects: 148
Study 19733016 — intervention group
Group type: COMPARATOR
Intervention: Postoperative conventional fractionation (p‐CF) therapy
Number of subjects: 148
Study 17965037 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol per day
Number of subjects: 218
Study 17965037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol per day
Number of subjects: 218
Study 17965037 — intervention group
Group type: COMPARATOR
Intervention: 0 IU cholecalciferol per day
Number of subjects: 218
Study 17965037 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 218
Study 16162258 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA)
Number of subjects: 169
Study 16162258 — intervention group
Group type: COMPARATOR
Intervention: Migraine without aura (MoA)
Number of subjects: 169
Study 15785177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 11756862 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex treatment
Number of subjects: 383
Study 11756862 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 383
Study 9370894 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg elemental zinc per day)
Number of subjects: 111
Study 1541219 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured and standardized history taking and clinical examination (test phase)
Number of subjects: 0
Study 1541219 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (test phase)
Number of subjects: 0
Study 1541219 — intervention group
Group type: COMPARATOR
Intervention: Baseline phase (clinical routine without additional intervention)
Number of subjects: 0
Study 4043200 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide treatment in patients with ascites
Number of subjects: 7
Study 4043200 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide treatment after resolution of ascites
Number of subjects: 7
Study 4043200 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide treatment in patients with diuretic resistant ascites
Number of subjects: 7
Study 4043200 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide treatment in patients with gross ascites
Number of subjects: 7
Study 29627695 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Resilience Training (MBRT)
Number of subjects: 61
Study 29627695 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 61
Study 27521483 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Number of subjects: 40
Study 27521483 — intervention group
Group type: COMPARATOR
Intervention: Low dose radiation (LDR)
Number of subjects: 40
Study 25471366 — intervention group
Group type: EXPERIMENTAL
Intervention: STI educational intervention (interactive training with basic STI knowledge, case scenarios, and poster distribution)
Number of subjects: 304
Study 25471366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 304
Study 25471366 — intervention group
Group type: EXPERIMENTAL
Intervention: STI educational intervention
Number of subjects: 304
Study 25471366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study 22845695 — intervention group
Group type: EXPERIMENTAL
Intervention: High cutoff (HCO) dialyzer (Gambro HCO1100)
Number of subjects: 19
Study 22845695 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-flux (HF) membrane
Number of subjects: 19
Study 20627818 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo expectation condition
Number of subjects: 0
Study 20627818 — intervention group
Group type: COMPARATOR
Intervention: No expectation condition
Number of subjects: 0
Study 18708258 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 10
Study 18708258 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 10
Study 16122495 — intervention group
Group type: EXPERIMENTAL
Intervention: Novare Enclose proximal anastomotic device
Number of subjects: 50
Study 12574564 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 915 mg over 1 hour followed by 420 mg/h for 71 hours
Number of subjects: 135
Study 12574564 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 1820 mg for 1 hour followed by 844 mg/h for 71 hours
Number of subjects: 135
Study 12574564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 12148471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone (2 mg/day for 5 days every month)
Number of subjects: 32
Study 12148471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 35 micrograms plus desogestrel 150 mg (21 days every month)
Number of subjects: 32
Study 10445964 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Lobe Personality Scale (FLOPS) completed by family members of frontal lobe patients post-lesion
Number of subjects: 87
Study 7845489 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory chest roentgenograms
Number of subjects: 59
Study 7845489 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory chest roentgenograms
Number of subjects: 59
Study 7845489 — intervention group
Group type: COMPARATOR
Intervention: Control roentgenograms
Number of subjects: 59
Study 2179857 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen, administered at 3, 4, and 6 months of age.
Number of subjects: 0
Study 2179857 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen.
Number of subjects: 0
Study 7398002 — intervention group
Group type: EXPERIMENTAL
Intervention: Persantine plus aspirin (PR/A)
Number of subjects: 2026
Study 7398002 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA)
Number of subjects: 2026
Study 7398002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLBO)
Number of subjects: 2026
Study 6339425 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-biofeedback relaxation training
Number of subjects: 24
Study 6339425 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation training
Number of subjects: 24
Study 6339425 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 24
Study 31544719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention
Number of subjects: 202
Study 31544719 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 202
Study 29788903 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 584
Study 29788903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study 27568513 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 0
Study 27568513 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone treatment
Number of subjects: 0
Study 24965385 — intervention group
Group type: EXPERIMENTAL
Intervention: Light mask that emits a dim green light worn every night for 12 months
Number of subjects: 60
Study 24965385 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study 22037139 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tDCS sessions
Number of subjects: 12
Study 22037139 — intervention group
Group type: COMPARATOR
Intervention: Second daily tDCS sessions
Number of subjects: 12
Study 20392706 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (defined as exercise frequency equal to or more than once/week)
Number of subjects: 20920
Study 20392706 — intervention group
Group type: COMPARATOR
Intervention: Exercise programmes offered at dialysis facilities
Number of subjects: 20920
Study 20392706 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 20920
Study 20392706 — intervention group
Group type: COMPARATOR
Intervention: Facilities with more regular exercisers
Number of subjects: 20920
Study 18455192 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA treatment
Number of subjects: 551
Study 18455192 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 551
Study 18455192 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure declines >50 mmHg
Number of subjects: 551
Study 18455192 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure declines >60 mmHg
Number of subjects: 551
Study 16180627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor agonist bromocriptine
Number of subjects: 0
Study 16180627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14516216 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with connected components in memory
Number of subjects: 0
Study 14516216 — intervention group
Group type: COMPARATOR
Intervention: Younger adults under divided-attention conditions
Number of subjects: 0
Study 14516216 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with unrelated attributes in memory
Number of subjects: 0
Study 10787766 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and dietary intervention
Number of subjects: 80
Study 10787766 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 10787766 — intervention group
Group type: EXPERIMENTAL
Intervention: All women (treatment and control)
Number of subjects: 80
Study 9000327 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator (mandibular advancement device)
Number of subjects: 15
Study 9000327 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-palate lifter
Number of subjects: 15
Study 9000327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-shield
Number of subjects: 15
Study 1289589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) administered at a mean dose of 8.6 mg/kg in 3-4 divided doses for an average of 7 days.
Number of subjects: 160
Study 1289589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) administered at doses of 4.0, 7.5, and 15.0 mg/kg to 9 children.
Number of subjects: 160
Study 6362388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 51
Study 6362388 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 51
Study 31218077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate 240 mg
Number of subjects: 52
Study 31218077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29888730 — intervention group
Group type: COMPARATOR
Intervention: intact teeth (control)
Number of subjects: 105
Study 29888730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribbond in the occlusal surface + composite resin (Group 6)
Number of subjects: 105
Study 29888730 — intervention group
Group type: EXPERIMENTAL
Intervention: horizontal fiber post + composite resin (Group 7)
Number of subjects: 105
Study 29888730 — intervention group
Group type: EXPERIMENTAL
Intervention: unfilled MOD cavity (Group 2)
Number of subjects: 105
Study 29888730 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD + composite resin (Group 3)
Number of subjects: 105
Study 29888730 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mm‐long fiber post + composite resin (Group 4)
Number of subjects: 105
Study 29888730 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mm‐long fiber post + composite resin (Group 5)
Number of subjects: 105
Study 26133538 — intervention group
Group type: EXPERIMENTAL
Intervention: α-galactosidase (AG)
Number of subjects: 125
Study 26133538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 25672160 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser myringotomy (LM)
Number of subjects: 66
Study 25672160 — intervention group
Group type: COMPARATOR
Intervention: Incisional myringotomy (classical myringotomy)
Number of subjects: 66
Study 23213982 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-needling group
Number of subjects: 120
Study 23213982 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy group
Number of subjects: 120
Study 23213982 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture group
Number of subjects: 120
Study 20933221 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention
Number of subjects: 60
Study 20933221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 18248689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (1.5mg)
Number of subjects: 23
Study 18248689 — intervention group
Group type: EXPERIMENTAL
Intervention: Meth (30mg)
Number of subjects: 23
Study 18248689 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23
Study 15796146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral egg albumin-based protein supplement
Number of subjects: 28
Study 15796146 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutritional counseling (Control)
Number of subjects: 28
Study 12188103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6-12 mg/day
Number of subjects: 0
Study 12188103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine from Day 1
Number of subjects: 0
Study 12188103 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with rivastigmine
Number of subjects: 0
Study 10390227 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (600 mg) alone
Number of subjects: 15
Study 10390227 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg) alone
Number of subjects: 15
Study 10390227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg) alone
Number of subjects: 15
Study 10390227 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of Abacavir with Zidovudine and Lamivudine
Number of subjects: 15
Study 10390227 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of Zidovudine and Lamivudine with Abacavir
Number of subjects: 15
Study 9273204 — intervention group
Group type: EXPERIMENTAL
Intervention: AKBR value higher than 0.7 (Group A, 8 subjects)
Number of subjects: 12
Study 9273204 — intervention group
Group type: EXPERIMENTAL
Intervention: AKBR between 0.4 and 0.7 (Group B, 2 cases)
Number of subjects: 12
Study 9273204 — intervention group
Group type: EXPERIMENTAL
Intervention: AKBR below 0.4 (Group C, 2 cases)
Number of subjects: 12
Study 9273204 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 persons)
Number of subjects: 12
Study 2005227 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (5 mg daily)
Number of subjects: 8
Study 2005227 — intervention group
Group type: COMPARATOR
Intervention: Control group (no folic acid supplementation)
Number of subjects: 8
Study 2005227 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 8
Study 6647195 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 6647195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29733982 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent navigator and a care notebook
Number of subjects: 300
Study 29733982 — intervention group
Group type: COMPARATOR
Intervention: Care notebook
Number of subjects: 300
Study 26713403 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg at baseline and 6 months)
Number of subjects: 90
Study 26713403 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 25918060 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1152
Study 25918060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1152
Study 25918060 — intervention group
Group type: COMPARATOR
Intervention: Conventional Medical Treatment Only (MTO)
Number of subjects: 1152
Study 25918060 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI screen-positive patients
Number of subjects: 1152
Study 25918060 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depressive disorder treated with escitalopram
Number of subjects: 1152
Study 23857024 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 279,396 (15% paromomycin + 0.5% gentamicin)
Number of subjects: 30
Study 23857024 — intervention group
Group type: COMPARATOR
Intervention: Paromomycin Alone (15% paromomycin)
Number of subjects: 30
Study 19943178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 75
Study 19943178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 75
Study 19943178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 75
Study 19943178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 18691845 — intervention group
Group type: EXPERIMENTAL
Intervention: Original consent document
Number of subjects: 22
Study 18691845 — intervention group
Group type: COMPARATOR
Intervention: Shortened version of consent document
Number of subjects: 22
Study 18691845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22